Mundipharma International

CAMBRIDGE, England - - Blood Marrow Normalised in 31% (Versus 2%) of Patients, With Manageable Side-Effects Nearly a third (31%) of all bendamustine-treated patients saw all clinical evidence of their advanced chronic lymphocytic leukaemia (CLL) disappear when used as a first-line treatment option, according to the results of a large new multicentre phase III study published online by the Journal of Clinical Oncology today.